With a new administration in Washington, drug policy experts are watching carefully who President-elect Donald Trump will nominate for a variety of roles within his cabinet.

Trump’s picks to lead the Department of Health and Human Services, DEA and FDA will affect harm reduction policies, policing and addiction treatment. 

The former (and future) president has a mixed record on battling the scourge of opioids. He created a commission to address the crisis during his first term, and he also declared a state of emergency; but he repeatedly tried to cut funding for the Office of National Drug Control Policy. 

Robert Kent, former general counsel in the White House Office of National Drug Control Policy under President Biden, former in-house counsel for OASAS and current president of Kent Strategic Advisors, spoke with Capital Tonight host Susan Arbetter.